Botulinum toxin type A

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cerebral Palsy

Conditions

Cerebral Palsy, Muscle Spasticity, Children

Trial Timeline

Oct 1, 2011 → Jan 1, 2015

NCT ID

NCT01251380

About Botulinum toxin type A

Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Cerebral Palsy. The current trial status is completed. This product is registered under clinical trial identifier NCT01251380. Target conditions include Cerebral Palsy, Muscle Spasticity, Children.

What happened to similar drugs?

5 of 16 similar drugs in Cerebral Palsy were approved

Approved (5) Terminated (1) Active (11)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅RosuvastatinAstraZenecaApproved

✅clopidogrel (SR25990C)SanofiApproved

✅PiracetamUCBApproved

✅Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.Brain BiotechApproved

🔄Oral Glycopyrrolate LiquidShionogiPhase 3

🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03017729	Pre-clinical	Completed	Feb 10, 2017	Nov 30, 2020	Lower Limb Spasticity
NCT02969356	Approved	Completed	Dec 18, 2016	Jul 1, 2018	Spastic Hemiparesis
NCT02020980	Pre-clinical	Completed	Apr 1, 2014	Mar 5, 2018	Lower Limb Spasticity
NCT02106351	Phase 3	Completed	Apr 1, 2014	Sep 4, 2018	Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
NCT01753336	Phase 3	Completed	Mar 1, 2013	Oct 1, 2015	Cervical Dystonia
NCT01753349	Pre-clinical	Completed	Dec 1, 2012	Sep 25, 2017	Cervical Dystonia
NCT01682148	Phase 3	Terminated	Sep 1, 2012	Mar 1, 2015	Arm Spasticity
NCT01313312	Phase 3	Completed	Nov 1, 2011	Dec 1, 2014	Nervous System Disorders
NCT01251380	Phase 3	Completed	Oct 1, 2011	Jan 1, 2015	Cerebral Palsy
NCT01251367	Phase 3	Completed	Jun 1, 2011	Apr 1, 2015	Post-stroke Spasticity
NCT00455637	Phase 2	Terminated	Mar 1, 2007	Mar 17, 2008	Cerebral Palsy
NCT00288509	Phase 3	Completed	Feb 1, 2006	Jan 1, 2008	Cervical Dystonia
NCT00276315	Phase 3	Completed	Dec 1, 2005	Jan 1, 2007	Hemifacial Spasm
NCT00246142	Phase 3	Completed	Apr 1, 2005	Jun 27, 2007	Myofascial Pain Syndromes
NCT00134810	Phase 2	Completed	Mar 1, 2005	May 18, 2006	Myofascial Pain Syndromes
NCT00149240	Phase 2	Completed	Jan 1, 2005	Feb 2, 2006	Myofascial Pain Syndromes
NCT00246155	Phase 3	Completed	Jan 1, 2005	Jul 1, 2005	Low Back Pain
NCT00447772	Phase 3	Completed	Oct 1, 2004	Apr 1, 2008	Cervical Dystonia
NCT00247559	Phase 2	Completed	May 1, 2004	Apr 8, 2005	Lateral Canthal Lines
NCT00210444	Phase 2	Completed	Jun 1, 2003	Dec 1, 2006	Anal Fissure

Competing Products

20 competing products in Cerebral Palsy

See all competitors

Product	Company	Stage	Hype Score
mouse nerve growth factor	Sun Pharmaceutical	Approved	39
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Oral Glycopyrrolate Liquid	Shionogi	Phase 3	40
recombinant human erythropoietin alfa + 0.9% NaCl	Johnson & Johnson	Phase 2/3	38
UDI-001	Rohto Pharmaceutical	Phase 1/2	32
NXY-059	AstraZeneca	Phase 3	40
NXY-059	AstraZeneca	Phase 2	35
Rosuvastatin	AstraZeneca	Approved	39
NXY-059	AstraZeneca	Phase 3	40
Comparator: Placebo + Comparator: MK0724	Merck	Phase 2	27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg	Merck	Phase 2	35
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
Ponezumab	Pfizer	Phase 2	35
PF-05230907	Pfizer	Phase 1	21
Azithromycin + Pyrimethamine + Leucovorin calcium	Pfizer	Phase 1	29
clopidogrel (SR25990C)	Sanofi	Approved	43
Intrarectal quinine	Sanofi	Phase 3	36
Piracetam	UCB	Approved	35
Placebo + ALN-APP	Alnylam Pharmaceuticals	Phase 2	39